---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015413"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:58:31.436301+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550

## Summary
- Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
- University of Minnesota will sponsor as investigator-initiated Phase 1a/1b trial.
- Budget of up to $3.8 million over three years, funded by GT Biopharma.
- Agreement effective April 3, 2026; 30-day termination clause for either party.

## SEC filing metadata
- accession: 0001493152-26-015413
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315226015413/0001493152-26-015413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315226015413/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015413
- JSON: https://secwatch.observer/filing/0001493152-26-015413.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015413.txt

## Key facts
- Material Agreements
  GT Biopharma, Inc. entered into Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota valued at up to approximately $3.8 million (effective 2026-04-03).
  - Action: entry
  - Agreement: license
  - Counterparty: the Regents of the University of Minnesota
  - Value: up to approximately $3.8 million
  - Effective: 2026-04-03
  source text: On April 3, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), entered into an Investigator Initiated Clinical Trial Agreement (the “Agreement”) with the Regents of the University of Minnesota (the “University”), pursuant to which, the University shall sponsor an Investigational New Drug (“IND”) application for IND 169118 GTB-5550 (the “Research Program”) and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, “GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy,” designed by University (the “Study”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315226015413/0001493152-26-015413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.